CMC Biotech Working Group
Version 2.1
This is a detailed case study to stimulate discussion around how the core principles contained in Q8(R2), Q9 and Q10 guidelines could be applied to product realisation programs for a biotechnology-derived monoclonal antibody.
Note: Due to COVID-19, shipping is delayed up to 2-3 weeks. Digital versions are available for download once purchased.